Trial Profile
A Prospective, Randomized, Double Blind, Parallel Group Study to Establish the Therapeutic Equivalence of EPIAO With the Standard Treatment EPREX in Subjects With Chronic Kidney Disease (CKD) Related Anaemia Not Yet on Dialysis
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Recombinant erythropoietin (Primary) ; Epoetin alfa
- Indications Anaemia; Renal failure
- Focus Therapeutic Use
- Acronyms BEAT_001
- Sponsors Shenyang Sunshine Pharmaceutical
- 19 Oct 2020 Status changed from recruiting to discontinued.
- 27 Apr 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 27 Apr 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.